Quantcast

Latest Institute for Quality and Efficiency in Health Care Stories

2013-12-05 23:48:03

No data on patients with metformin intolerance or contraindication The drug saxagliptin (trade name: Onglyza) has been approved also as monotherapy in Germany since July 2013 for certain adults with type 2 diabetes mellitus. It is an option when drug treatment is needed, but the drug metformin is not tolerated or cannot be used. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency...

2013-12-02 21:34:45

Procedure for report production and section on meta-analyses updated / New sections on early benefit assessment The German Institute for Quality and Efficiency in Health Care (IQWiG) has completed the first step in the revision of its methods paper and published the version “General Methods 4.1” on the Internet on 28 November 2013. From now on the new document forms the basis for the scientific work of the Institute and its external experts and for collaboration with the commissioning...

2013-11-18 20:56:37

Hardly any patient-relevant outcomes were investigated / studies without control groups The drug vismodegib (trade name: Erivedge) is approved for the treatment of patients with two forms of basal cell carcinoma (BCC): symptomatic metastatic BCC and locally advanced BCC inappropriate for surgery or radiotherapy. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care...

2013-10-30 15:52:03

Report on health economic evaluation of antidepressants provides very helpful results / Discussion is still pending about the future role of health economic evaluations in the health care system The German Institute for Quality and Efficiency in Health Care (IQWiG) has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the “efficiency frontier method” works and can provide very helpful results. In relation to their...

2013-08-28 21:39:55

Comparative studies on benefit are missing / Data on diagnostic and prognostic accuracy lack informative value The patient-relevant benefit of positron emission tomography (PET) in oesophageal cancer, alone or in combination with computed tomography (CT), is not proven due to a lack of comparative studies. In terms of their diagnostic and prognostic accuracy, it also remains unclear whether these diagnostic techniques can detect the spreading of tumors better than conventional diagnostics....

2013-07-25 10:08:59

Now proof of minor added benefit in severe cases or recurrences of Clostridium difficile infections In the commenting procedure on early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products (AMNOG), under certain circumstances drug manufacturers may submit to the Federal Joint Committee (G-BA) additional documents for dossiers. The Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed such additional information for two...

2013-07-11 16:05:38

Indication of considerable added benefit for overall survival / indications of greater harm from side effects The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German...

2013-06-06 11:42:47

Manufacturer's dossier did not contain any relevant data for the comparison with diclofenac/hyaluronic acid gel The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new...

2013-06-05 11:53:36

Manufacturer's dossier did not contain any usable data for the comparison with ranibizumab The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.